Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Key Stats

• Today's Range: $2.90 to $2.98
• 50-Day Range: $2.45 to $7.04
• 52-Week Range: $2.27 to $26.05
• Volume: 75,735 shs
• Average Volume: 496,599 shs
• Market Capitalization: $47.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.75
• Consensus Rating: Moderate Buy

Jasper Therapeutics Stock Analysis - MarketRank™

Jasper Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 459th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jasper Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jasper Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($4.47) to ($4.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jasper Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jasper Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jasper Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.25% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jasper Therapeutics does not currently pay a dividend.

Dividend Growth

Jasper Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.25% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.53

News Sentiment

Jasper Therapeutics has a news sentiment score of -0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Jasper Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -87% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Jasper Therapeutics is held by insiders.

Percentage Held by Institutions

79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JSPR Stock Analysis - Frequently Asked Questions

How have JSPR shares performed this year?

Jasper Therapeutics' stock was trading at $21.38 at the beginning of 2025. Since then, JSPR stock has decreased by 86.4% and is now trading at $2.9050.

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.54.

When did Jasper Therapeutics' stock split?

Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' top institutional investors include Bank of America Corp DE (1.95%), Bank of Montreal Can (1.05%), Jane Street Group LLC (0.88%) and Geode Capital Management LLC (0.87%). Insiders that own company stock include Velan Capital Investment Manag, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and Anna Louise French.
View institutional ownership trends.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jasper Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/27/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JSPR
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jasper Therapeutics: $28.75
• High Price Target: $65.00
• Low Price Target: $5.00
• Potential Upside/Downside: +874.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -172.28%
• Return on Assets: -128.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.10
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.45 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 16,253,000
• Free Float: 15,505,000
• Market Cap: $47.96 million
• Optionable: Optionable
• Beta: 2.70